DMII Stock — Drugs Made In America Acquisition II Corp. Ordinary Shares

Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII)

Updated October 16, 2026.

DMII is a Stock. Total return is 3.0% over the past 0.9 years, 9.8 points behind SPY at 12.8%.

Drugs Made In America Acquisition II Corp. is a blank-check company incorporated in 2024 that seeks to identify and complete a business combination with one or more companies in the pharmaceutical sector. The company currently has no significant operations and is in the process of sourcing and evaluating potential acquisition targets. This security does not currently distribute income and appeals primarily to investors interested in participating in a pharmaceuticals-focused merger or acquisition.

DMII performance versus SPY

Price and return data through 2026-10-16.

Total return is 3.0% over the past 0.9 years, 9.8 points behind SPY at 12.8%. Its deepest 1-year drawdown was 0.7%.

DMII key facts

Asset type

Stock

Asset class

Equity

Inception date

12/03/2025

Distribution frequency

None

Last close

$10.18 (as of 2026-10-16)

Market cap

$648,466,000

Average volume

1043043.0

Beta

-0.0052

Payout ratio

0.0%

P/E ratio

33.93

EPS

$0.30

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

DMII risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 0.7%.

Who may consider DMII — and who may not

It is a weaker fit for investors who need monthly cash flow (DMII does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on DMII

• All tickers starting with D

Tagged: Financials.

Frequently asked questions